DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2333625/travere-gains-11-on-securing-full-fda-nod-for-kidney-disease-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2333625 Sep 09, 2024 - The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities. 0

https://www.zacks.com/stock/news/2334138/relay-stock-soars-on-upbeat-data-from-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334138 Sep 10, 2024 - RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC. 0

https://www.zacks.com/stock/news/2194044/what-makes-wolters-kluwer-nv-wtkwy-a-good-fit-for-trend-investing?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2194044 Dec 06, 2023 - Wolters Kluwer NV (WTKWY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. 0

https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200063 Dec 19, 2023 - Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe. 0

https://www.zacks.com/stock/news/2200609/roche-s-rhhby-sbla-for-xolair-gets-fda-priority-review-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200609 Dec 20, 2023 - The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024. 0

https://www.zacks.com/stock/news/2205112/voyager-vygr-gains-on-gene-therapy-deal-with-novartis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205112 Jan 03, 2024 - Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway. 0

https://www.zacks.com/stock/news/2205605/biotech-stock-roundup-vygr-gains-from-nvs-deal-agio-up-on-study-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2205605 Jan 04, 2024 - Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week. 0

https://www.zacks.com/commentary/2206306/top-analyst-reports-for-merck-salesforce-philip-morris?cid=CS-ZC-FT-research_daily-2206306 Jan 05, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM). 0

https://www.zacks.com/stock/news/2206930/the-zacks-analyst-blog-highlights-merck-salesforce-philip-morris-international-novartis-and-cme-group?cid=CS-ZC-FT-press_releases-2206930 Jan 08, 2024 - Merck, Salesforce, Philip Morris International, Novartis and CME Group are part of the Zacks top Analyst Blog. 0

https://www.zacks.com/commentary/2214881/top-research-reports-for-novartis-amgen-palo-alto-networks?cid=CS-ZC-FT-research_daily-2214881 Jan 24, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Amgen Inc. (AMGN) and Palo Alto Networks, Inc. (PANW). 0